(Sharecast News) - Syncona said in an update on Wednesday that its portfolio company Beacon Therapeutics has reported encouraging six-month interim results from its phase two 'DAWN' trial, marking a key milestone in the development of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP).
The FTSE 250 company said the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE